ADMET

Simulations Plus Releases ADMET Predictor Version 10.4 (X.4)

Retrieved on: 
Donnerstag, Mai 26, 2022
Science, Software, Other Science, Pharmaceutical, Internet, General Health, Health, Technology, Mission statement, Software, Economics, Company, Population, Biophysical environment, U.S. Securities and Exchange Commission, Nasdaq, SLP, Solution, Drug design, ADMET, Pharmacokinetics, Simulations Plus, Research, Cheminformatics, Biotechnology, Roche, Technology, Risk, LinkedIn, Private Securities Litigation Reform Act, 3D, Drug discovery, ESG, 3D printing

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of version 10.4 (X.4) of its flagship machine learning modeling platform, ADMET Predictor .

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today announced the release of version 10.4 (X.4) of its flagship machine learning modeling platform, ADMET Predictor .
  • Simulations Plus remains committed to developing and improving state-of-the-art property prediction models, integrating the best and most innovative science, and advancing artificial intelligence-driven drug design.
  • We are excited to get this new version into the hands of our growing user community to take drug discovery research to the next level.
  • Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions.

UPDATE: Gb Sciences Issues Shareholder Letter

Retrieved on: 
Mittwoch, März 16, 2022
CRO, Absorption, Contract research organization, Nature, Water, US FDA, OTCQB, INC, Mouth, CRS, CEO, THE, U.S. Securities and Exchange Commission, Metabolism, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Contract, Letter, GBLX, COVID-19, COVID, Time Release (novel), IND, National Research Council Canada, Clinical trial, University, Depression, ADMET, US, Patient, Cytokine release syndrome, Parkinson's disease, Hospital, Anxiety, Security (finance), Investigational New Drug, Sale, Food, Chronic pain, Nanoparticle, University of Seville, GLOBE, Drug discovery, National Research Council, Chemistry, Cannabis, CMC, Safety, Company, University of Lethbridge, Good manufacturing practice, Michigan State University, Pharmaceutical industry, Generic drug, Toxicology, Lethbridge

A MESSAGE FROM BOTH THE PRESIDENT AND THE CHAIRMAN OF GB SCIENCES, INC.

Key Points: 
  • A MESSAGE FROM BOTH THE PRESIDENT AND THE CHAIRMAN OF GB SCIENCES, INC.
  • The ability to up list increases the opportunities for Gb Sciences to attract investment and development partners to bring our promising formulations into human clinical trials.
  • Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 18 U.S. and 49 foreign patent-pending applications.
  • Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada.

Gb Sciences Issues Summary Shareholder Letter

Retrieved on: 
Dienstag, März 15, 2022
CRO, Absorption, National Research Council Canada, Letter, Contract research organization, Depression, ADMET, University, University of Seville, GLOBE, GBLX, Patient, Cytokine release syndrome, Parkinson's disease, Drug discovery, National Research Council, Hospital, Contract, Chemistry, COVID-19, Nature, Water, Cannabis, Anxiety, CMC, OTCQB, Security (finance), COVID, Mouth, IND, Time Release (novel), Investigational New Drug, Clinical trial, CRS, Sale, Company, CEO, University of Lethbridge, Good manufacturing practice, Chronic pain, U.S. Securities and Exchange Commission, Michigan State University, Metabolism, Nanoparticle, Pharmaceutical industry, Generic drug, Toxicology, Lethbridge

The ability to up list increases the opportunities for Gb Sciences to attract investment and development partners to bring our promising formulations into human clinical trials.

Key Points: 
  • The ability to up list increases the opportunities for Gb Sciences to attract investment and development partners to bring our promising formulations into human clinical trials.
  • In addition, Gb Sciences has other promising late-preclinical stage programs, including our COVID-related cytokine release formulations and our time-released oral nanoparticle formulations for chronic pain.
  • Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 18 U.S. and 49 foreign patent-pending applications.
  • Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada.

Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules

Retrieved on: 
Donnerstag, Februar 17, 2022
Patient, CEO, Special-purpose acquisition company, Company, Perception, SEDAR, Phrase, Forward-looking statement, Review, Intention, Therapy, FSE, Person, Artificiality, Patent, Public opinion, News, NEO, ADMET, Pharmaceutical industry, Fine chemical, Audit, Security (finance)

Entactogen NCE Series Enhances the Potential to Treat a Broad Range of Addictions

Key Points: 
  • Entactogen-like molecules are a class of psychoactive substances that produce distinctive emotional and social effects that Awakn believes has great potential to treat both substance and behavioural addictions.
  • Awakn's latest patent application, which covers the new chemical series, fulfils another significant step forward in the development of next generation entactogens and provides a key milestone in Awakn's drug discovery program.
  • These molecules have the potential to revolutionize the treatment of addiction by delivering improved efficacy in a shorter treatment time.
  • About Awakn Life Sciences Corp.
    Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction.

XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform

Retrieved on: 
Mittwoch, Januar 19, 2022
Online, Algorithm, Data, SAR, Database, Safety, Machine learning, Drug design, Solution, Data Analytics Acceleration Library, Development, API, Intelligence, ISCB Senior Scientist Award, NLP, Artificial intelligence, Efficiency, Drug development, ADMET, Physics, Drug discovery, Partnership, Fine chemical, Medical device, Pharmaceutical industry

Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership.

Key Points: 
  • Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership.
  • Norman Azoulay, Product Leader, Excelra, said, "Artificial Intelligence and Machine Learning is bringing a paradigm shift to drug discovery and development.
  • XtalPi is a pharmaceutical technology company that is reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform.
  • The Excelra Edge comes from harmonizing heterogeneous data sets, applying innovative bioinformatics know-how and technologies to accelerate your drug discovery & development with reliable and result-oriented insights.

XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform

Retrieved on: 
Mittwoch, Januar 19, 2022
Online, Algorithm, Data, SAR, Database, Safety, Machine learning, Drug design, Solution, Data Analytics Acceleration Library, Development, API, Intelligence, ISCB Senior Scientist Award, NLP, Artificial intelligence, Efficiency, Drug development, ADMET, Physics, Drug discovery, Partnership, Fine chemical, Medical device, Pharmaceutical industry

Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership.

Key Points: 
  • Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership.
  • Norman Azoulay, Product Leader, Excelra, said, "Artificial Intelligence and Machine Learning is bringing a paradigm shift to drug discovery and development.
  • XtalPi is a pharmaceutical technology company that is reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform.
  • The Excelra Edge comes from harmonizing heterogeneous data sets, applying innovative bioinformatics know-how and technologies to accelerate your drug discovery & development with reliable and result-oriented insights.

Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™

Retrieved on: 
Donnerstag, Dezember 2, 2021
Data Management, Health, Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology, University, Biophysical environment, Risk, Technology, Private Securities Litigation Reform Act, Company, Hospital, Population, Awareness, Mission statement, ESG, Simulations Plus, Economics, Pharmacokinetics, Solution, Laboratory, SLP, U.S. Securities and Exchange Commission, Software, Nasdaq, Twitter, Research, Biotechnology, Drug discovery, ADMET, Pharmaceutical industry

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has extended its distributor agreement in Japan with Northern Science Consulting for Monolix.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has extended its distributor agreement in Japan with Northern Science Consulting for Monolix.
  • Jonathan Chauvin , President of the Lixoft division, said: We are excited to be partnering with Northern Science Consulting to further serve the needs of the Japanese scientific markets.
  • We are pleased with this agreement as Northern Science Consulting is a well-recognized company in Japan and is already successful in distributing Simulations Plus.
  • Goh Murakami, Chief Executive Officer at Northern Science Consulting Inc., said: Founded in 2004, Northern Science Consulting in Japan strongly supports biological science research and development through the provision and support of software.

Silexon Partners with Excelra, Deploying GOSTAR to Strengthen its AI-driven Drug Discovery and Biopharmaceutical Research Platform

Retrieved on: 
Mittwoch, Dezember 1, 2021
Online, Patient, CEO, Data, Sutro Biopharma, Partnership, Machine learning, ADMET, D, Global Online Laboratory Consortium, Solution, Drug design, Database, Artificial intelligence, Identification, SAR, ADME, Drug discovery, Medical device

Under the agreement, Excelra will provide ADMET and Binding Assays datasets from its GOSTAR database to Silexon.

Key Points: 
  • Under the agreement, Excelra will provide ADMET and Binding Assays datasets from its GOSTAR database to Silexon.
  • Silexon focuses on innovative biomedicines with unique target product profiles for undruggable, difficult-to-drug, and novel targets in multiple therapeutic areas.
  • We are delighted to partner with Silexonand to be part of their journey in developing the AI4D platform for drug discovery."
  • Using our AI/ML platform, we aim to address bottlenecks in drug discovery and biopharmaceutical research to ultimately deliver innovative therapeutic candidates with higher overall success rates.

Silexon Partners with Excelra, Deploying GOSTAR to Strengthen its AI-driven Drug Discovery and Biopharmaceutical Research Platform

Retrieved on: 
Mittwoch, Dezember 1, 2021
Online, Patient, CEO, Data, Sutro Biopharma, Partnership, Machine learning, ADMET, D, Global Online Laboratory Consortium, Solution, Drug design, Database, Artificial intelligence, Identification, SAR, ADME, Drug discovery, Medical device

Under the agreement, Excelra will provide ADMET and Binding Assays datasets from its GOSTAR database to Silexon.

Key Points: 
  • Under the agreement, Excelra will provide ADMET and Binding Assays datasets from its GOSTAR database to Silexon.
  • Silexon focuses on innovative biomedicines with unique target product profiles for undruggable, difficult-to-drug, and novel targets in multiple therapeutic areas.
  • We are delighted to partner with Silexonand to be part of their journey in developing the AI4D platform for drug discovery."
  • Using our AI/ML platform, we aim to address bottlenecks in drug discovery and biopharmaceutical research to ultimately deliver innovative therapeutic candidates with higher overall success rates.

Global Spectrometry Market Size, Share, Trends Analysis & Forecasts Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Dienstag, November 23, 2021
Science, Other Science, Other Manufacturing, Manufacturing, Patient, Technology, DMPK, Diagnosis, Waters Corporation, Absorption, Shimadzu, Blood, Thermo Fisher Scientific, Metabolism, Research, Organization, Agilent Technologies, College of Arts and Sciences, Drug development, Drug discovery, Growth, ADMET, Amyloid, Immunoprecipitation, Pharmaceutical industry, Fine chemical, Lithium

The "Global Spectrometry Market Size, Share & Trends Analysis Report by Type, by Product, by Application (Pharmaceutical Analysis, Forensic Analysis, Proteomics, Metabolomics), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Spectrometry Market Size, Share & Trends Analysis Report by Type, by Product, by Application (Pharmaceutical Analysis, Forensic Analysis, Proteomics, Metabolomics), by End-use, by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.
  • Key players offer technologically advanced spectrometry products for several healthcare applications and have collaborated with research institutes to develop novel products.
  • The market is expected to show potential growth in the coming future owing to the introduction of healthcare services using MALDI-TOF mass spectrometry (MS) by key players operating in the market.
  • Hence, the application of spectrometry in drug development is anticipated to show potential growth during the forecast period.